GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

APYX · Mar 31, 2026

Apyx Medical Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-26-015652General Corporate
Debt relative to revenue63thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.debt_to_revenue

300.24% · OPTIONAL · VALID

Capex intensity7thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.48% · OPTIONAL · VALID

Operating cash generation93thOwn-history percentile · N=14
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-4.58% · OPTIONAL · VALID

Revenue growth100thOwn-history percentile · N=10
Evidence method

Yoy · gp.fundamentals.revenue

32.45% · CORE · VALID

Inventory pressure43thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

76.35% · OPTIONAL · VALID

Gross margin64thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.gross_margin

63.45% · CORE · VALID

Operating margin93thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.operating_margin

-7.29% · CORE · VALID

R&D intensity0thOwn-history percentile · N=14
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

6.12% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=14
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.50% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/9 normalizedLevel 3Dec 31, 20247/9 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20269/9 normalizedLevel 3Jun 30, 20269/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
70.96%
Current
300.24%
Delta
229.28%
Capex Intensity Decreased
Previous
2.11%
Current
0.48%
Delta
-1.63%
Cash Generation Increased
Previous
-15.14%
Current
-4.58%
Delta
10.56%
Growth Increased
Previous
9.86%
Current
32.45%
Delta
22.59%
Inventory Pressure Increased
Previous
16.28%
Current
76.35%
Delta
60.07%
Margin Increased
Previous
62.53%
Current
63.45%
Delta
0.92%
Profitability Increased
Previous
-12.20%
Current
-7.29%
Delta
4.90%
R And D Intensity Decreased
Previous
6.38%
Current
6.12%
Delta
-0.26%
Sbc Intensity Decreased
Previous
3.79%
Current
2.50%
Delta
-1.29%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · APYX Fundamental State →Transitioned To · APYX BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · APYX CAPEX_INTENSITY_DECREASED →Transitioned To · APYX CASH_GENERATION_INCREASED →Transitioned To · APYX GROWTH_INCREASED →Transitioned To · APYX INVENTORY_PRESSURE_INCREASED →Transitioned To · APYX MARGIN_INCREASED →Transitioned To · APYX PROFITABILITY_INCREASED →Transitioned To · APYX R_AND_D_INTENSITY_DECREASED →Transitioned To · APYX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.